In combination, this prior literature provides a rationale as to why LOX-1 may be elevated in patients with CCM, and we hypothesize that LOX-1 overexpression is a secondary effect of the ischemia and altered cerebrovascular hemodynamics that are well-documented in CCM. The gene discussed is OLR1; the disease is cerebral cavernous malformation.